

AI
cont.

58. The pharmaceutical composition of claim 52, wherein the carrier is a sterile, buffered, injectable carrier.

59. A pharmaceutical composition suitable for treating a pathogenic infection comprising the polypeptide of claim 1 and a pharmaceutically acceptable carrier.

APR 17 2000

TECH CENTER 1600/2900

REMARKS

APR 17 2000

TECH CENTER 1600/2900

Applicants respectfully request entry of the present Preliminary Amendment. New claims 52-59 have been added to more clearly define the pharmaceutical compositions of the invention. No new matter has been added. Applicants respectfully request consideration of the pending claims and new claims. Support for the term "pharmaceutical composition" can be found on page 24, line 18 of the specification. Support for the term "delivery vehicle" can be found on page 34, line 16 of the specification. Support for the term "liposome" can be found on page 34, line 16 of the specification. Support for the term "unit dosage" can be found on page 34, lines 30-31, bridging to page 35, lines 1-4 of the specification. Support for the term "pathogenic" can be found on page 50, line 28 of the specification. Applicants maintain that the pending claims clearly and patentably define the invention. Applicants submit that all of the claims are now in condition for examination, which action is requested.

If the Examiner would like to discuss any of the issues raised in this correspondence, Applicants' representative would welcome the opportunity. Applicants' representative can be reached at (858) 678-5070. Applicants do not believe that any fees are due with the present amendment. If, however, it is determined that fees are owed, please apply any charges or credits to Deposit Account No. 06-1050.

Respectfully submitted,

Date: 5/5/00



Michael Reed, Ph.D.
Reg. No. P-45,647
Applicants' Representative

Fish & Richardson P.C.
4350 La Jolla Village Drive, Suite 500
San Diego, CA 92122
Telephone: (858) 678-5070
Facsimile: (858) 678-5099
10022877.doc